drugset / Trial / NCT06699329

A Study of Enlicitide Decanoate (MK-0616) and Semaglutide in Healthy Adult Participants (MK-0616-023)

NCT06699329

Phase 1 Completed 38 enrolled Merck Sharp & Dohme LLC
NaSingle-groupOpen-labelBasic science

Summary

The goal of this study is to learn what happens in a person's body over time when they take enlicitide decanoate and semaglutide alone or at the same time. Enlicitide decanoate is a new medicine that lowers the amount of cholesterol in a person's blood. Semaglutide is a drug used to treat type 2 diabetes. Researchers want to learn what happens to the amount of semaglutide and enlicitide decanoate in a person's blood when each drug is taken alone and when they are taken together.

Timeline

Start
2024-01-22
Primary completion
2024-05-24
Completion
2024-05-24

Drugs

EvaluationDrugModalityDoseRoute
Subject Enlicitide Decanoate Unknown Oral
Subject Semaglutide Peptide Oral

Indications

No indication recorded.